Discussion of “Some Controversial Multiple Testing Problems in Regulatory Applications”

We appreciate the opportunity to comment on this paper. We focus on two issues in the “multiple doses and multiple endpoints” setting. The first issue is, as pointed out by the authors, whether inf...